Gate Diagnostics Granted First Patent in Europe for Diagnostic Technology Platform

[Milpitas, California] — Gate Diagnostics is proud to announce that the company has been granted its first European patent covering its core diagnostic technology platform. This milestone represents an important step in protecting Gate Diagnostics’ intellectual property and advancing its mission to develop innovative, accessible diagnostic solutions for veterinary medicine.

The newly granted patent strengthens Gate Diagnostics’ growing intellectual property portfolio and reflects the novelty of the company’s underlying approach to molecular diagnostics. The protected technology supports the development of rapid, flexible, and scalable testing platforms, including Sequre™, Gate Diagnostics’ molecular platform for equine respiratory disease. Together, these innovations are designed to help bring high-performance diagnostics closer to the point of care.

“This patent not only protects our technology, but also reinforces our long-term commitment to innovation in veterinary diagnostics,” said the Gate Diagnostics team. “We are excited to continue building a strong foundation for future product development as we work to improve disease detection, treatment decisions, and biosecurity across animal health.”